{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:38:26Z","timestamp":1789601906392,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.gtc.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:55:29Z","timestamp":1781726129000},"page":"503-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Food and Drug Administration\u2013Approved Fecal Microbiota\u2013Based Therapies for Recurrent Clostridioides difficile Infection"],"prefix":"10.1016","volume":"55","author":[{"given":"Parul","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gtc.2026.05.010_bib1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.010_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/501553","article-title":"Recurrent Clostridium difficile disease: epidemiology and clinical characteristics","volume":"20","author":"McFarland","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.010_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.010_bib4","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the infectious diseases society of America (IDSA) and Society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2026.05.010_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European society of clinical microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.010_bib6","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.mayocp.2021.03.033","article-title":"My treatment approach to Clostridioides difficile infection","volume":"96","author":"Khanna","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.010_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA Clinical Practice Guideline on fecal microbiota\u2013based therapies for select gastrointestinal diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.010_bib8","article-title":"Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.010_bib9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2022.09.008","article-title":"Effectiveness and safety of colonic and capsule fecal microbiota transplantation for recurrent Clostridioides difficile infection","volume":"21","author":"Vaughn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.010_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11894-025-01030-1","article-title":"Fecal microbiota transplantation in 2025: two steps forward, one step back","volume":"28","author":"Miller","year":"2026","journal-title":"Curr Gastroenterol Rep"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.010_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S2468-1253(23)00357-6","article-title":"Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics","volume":"9","author":"Porcari","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.010_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.14309\/ajg.0000000000001075","article-title":"Fecal microbiota transplantation: the evolving risk landscape","volume":"116","author":"Gupta","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.010_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/gutjnl-2025-336532","article-title":"Towards optimising and standardising donor screening for faecal microbiota transplantion","volume":"75","author":"Liu","year":"2026","journal-title":"Gut"},{"issue":"1S","key":"10.1016\/j.gtc.2026.05.010_bib14","article-title":"Future microbiome therapeutics for Clostridioides difficile infection","volume":"119","author":"Fischer","year":"2024","journal-title":"Official Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.010_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.010_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2402550","article-title":"End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics","volume":"16","author":"Goldsmith","year":"2024","journal-title":"Gut Microbes"},{"issue":"1S","key":"10.1016\/j.gtc.2026.05.010_bib17","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.14309\/ajg.0000000000002577","article-title":"Prescription microbiome therapeutic for recurrent Clostridioides difficile infection: fecal microbiota live-jslm","volume":"119","author":"Oneto","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.010_bib18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.14309\/ajg.0000000000002195","article-title":"Practical use of RBX2660 for the prevention of recurrent Clostridioides difficile infection","volume":"118","author":"Feuerstadt","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.010_bib19","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1093\/infdis\/jiae418","article-title":"Microbiome and metabolome restoration after administration of fecal microbiota, live-jslm (REBYOTA) for preventing recurrent Clostridioides difficile infection","volume":"231","author":"Blount","year":"2025","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.010_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cell.2023.02.034","article-title":"Fecal microbiota-based treatment for recurrent Clostridioides difficile infection","volume":"186","author":"Walter","year":"2023","journal-title":"Cell"},{"issue":"suppl_1","key":"10.1016\/j.gtc.2026.05.010_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/ofid\/ofw172.1044","article-title":"Efficacy and safety of RBX2660 for the prevention of recurrent Clostridium difficile infection: results. of the PUNCH CD 2 trial","volume":"3","author":"Dubberke","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.010_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40121-022-00744-3","article-title":"Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection","volume":"12","author":"Dubberke","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.010_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz095","article-title":"Restoration of bacterial microbiome composition and diversity among treatment responders in a phase 2 trial of RBX2660: an investigational microbiome restoration therapeutic","volume":"6","author":"Blount","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.010_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13073-021-00843-9","article-title":"Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study","volume":"13","author":"Langdon","year":"2021","journal-title":"Genome Med"},{"issue":"15","key":"10.1016\/j.gtc.2026.05.010_bib25","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.010_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40121-023-00907-w","article-title":"Efficacy and health-related quality of life impact of fecal microbiota, live-jslm: a post hoc analysis of PUNCH CD3 patients at first recurrence of Clostridioides difficile infection","volume":"13","author":"Feuerstadt","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.010_bib27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/MCG.0000000000001947","article-title":"Fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection : subgroup analysis of PUNCH CD2 and PUNCH CD3","volume":"58","author":"Feuerstadt","year":"2024","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.010_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf117","article-title":"Safety and efficacy of fecal microbiota, live-jslm, in preventing recurrent Clostridioides difficile infection in participants who were mildly to moderately immunocompromised in the phase 3 PUNCH CD3-OLS study","volume":"12","author":"Alonso","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.gtc.2026.05.010_bib29","article-title":"Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA(\u00ae)) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial","volume":"18","author":"Khanna","year":"2025","journal-title":"Therapeut Adv Gastroenterol"},{"issue":"1S","key":"10.1016\/j.gtc.2026.05.010_bib31","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.14309\/ajg.0000000000002582","article-title":"Efficacy and practical implementation of fecal microbiota spores, Live-BRPK: a novel approach for preventing recurrent Clostridioides difficile infection","volume":"119","author":"Feuerstadt","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.010_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac448","article-title":"Manufacturing process of SER-109, a purified investigational microbiome therapeutic, reduces risk of coronavirus transmission from donor stool","volume":"9","author":"McChalicher","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.010_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41591-025-04076-w","article-title":"The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome","volume":"32","author":"Bryant","year":"2026","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.010_bib34","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","article-title":"SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial","volume":"72","author":"McGovern","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.010_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55758","article-title":"Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial","volume":"6","author":"Sims","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.010_bib36","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/cid\/ciad448","article-title":"Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic","volume":"77","author":"Berenson","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.gtc.2026.05.010_bib37","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s40121-024-01007-z","article-title":"Integrated safety and efficacy analyses of phase 3 trials of a microbiome therapeutic for recurrent CDI","volume":"13","author":"Kraft","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.010_bib38","doi-asserted-by":"crossref","first-page":"e1195","DOI":"10.1093\/cid\/ciac554","article-title":"Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a phase 3 randomized trial","volume":"76","author":"Lapin","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.010_bib39","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1093\/infdis\/jiaf408","article-title":"Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infection","volume":"232","author":"Bryant","year":"2025","journal-title":"J Infect Dis"},{"issue":"16","key":"10.1016\/j.gtc.2026.05.010_bib40","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jama.2023.4314","article-title":"VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial","volume":"329","author":"Louie","year":"2023","journal-title":"JAMA"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855326000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855326000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:31:25Z","timestamp":1786977085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855326000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889855326000385"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2026.05.010","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Food and Drug Administration\u2013Approved Fecal Microbiota\u2013Based Therapies for Recurrent Clostridioides difficile Infection","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}